$1.92
+0.08 (+4.35%)
PPCB News3 articles
Propanc Biopharma Plunges 19% Premarket After 108% Surge on PRP Data
Propanc Biopharma (PPCB) shares dropped 19.3% premarket to $1.80 after a 108% surge on PRP data. Despite strong animal results, revenue and cash concerns persist.
Propanc Biopharma Rockets 151% on Promising PRP Pancreatic Cancer Data
Propanc Biopharma (PPCB) shares jumped 151% after PRP reduced tumor growth by over 90% in pancreatic cancer models, with volume nearly 20 times normal.
Propanc Biopharma Soars After Announcing $5M Stock Buyback
Propanc Biopharma shares skyrocketed after the company authorized a $5 million stock buyback, surpassing its entire market value. Investors now watch for progress on its cancer drug PRP.